Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial
-
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Keedy, Vicki (Vanderbilt University Medical Center) ;
Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ;
Shepherd, Frances A. (University of Toronto) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Brown, Holly (Merck & Co., Inc., Whitehouse Station) ;
Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ;
Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ;
Reilly, John F.. (Merck & Co., Inc., Whitehouse Station) ;
Mauro, David (Merck & Co., Inc., Whitehouse Station) ;
Hsu, Karl (Sanofi Aventis) ;
Yan, Li (Merck & Co., Inc., Whitehouse Station) ;
Universitat Autònoma de Barcelona